Single-oral-dose azithromycin prophylaxis against experimental streptococcal or staphylococcal aortic valve endocarditis.
Azithromycin and ampicillin protected 94 and 72% of animals challenged with Streptococcus oralis, respectively (P = 0.177), while azithromycin and vancomycin protected 59 and 94% of the methicillin-resistant Staphylococcus aureus (MRSA)-challenged animals, respectively (P = 0.018). Azithromycin is effective in preventing experimental streptococcal endocarditis, but against MRSA it is less effective than vancomycin.
Tsitsika
A
A
Infectious Diseases Section, 4th Department of Medicine, Sismanoglion General Hospital, Athens University School of Medicine, Athens, Greece.
Pefanis
A
A
Perdikaris
G S
GS
Donta
I
I
Karayiannakos
P
P
Giamarellou
H
H
D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001021:Aortic Valve / Q000382:microbiology; D017963:Azithromycin / Q000008:administration & dosage*; D004697:Endocarditis, Bacterial / Q000188:drug therapy*; D005260:Female; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013290:Streptococcal Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D017963:Azithromycin